toripalimab + cetuximab + cisplatin + fluorouracil

This combination therapy consists of the PD-1 inhibitor toripalimab, the EGFR-targeted monoclonal antibody cetuximab, and the chemotherapy agents cisplatin and fluorouracil (5-FU). It is being evaluated by the First Affiliated Hospital of Zhejiang University as a conversion therapy for patients with initially unresectable locally advanced oral cavity squamous cell carcinoma (OCSCC). Toripalimab (JS001) is a humanized IgG4 monoclonal antibody that blocks the PD-1 receptor on T cells, preventing its interaction with PD-L1 and PD-L2 to restore anti-tumor immune responses. Cetuximab is a chimeric monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor (EGFR), inhibiting downstream signaling pathways involved in cell proliferation and survival. Cisplatin is a platinum-based chemotherapeutic that forms DNA cross-links, while fluorouracil is an antimetabolite that inhibits thymidylate synthase, both leading to DNA damage and apoptosis in rapidly dividing cancer cells.

Brand names

Tuoyi + Erbitux + cisplatin + fluorouracil

Other names

toripalimab + cetuximab + cisplatin + 5-FU